Abbott announces FDA approval and U.S. launch of next-generation XIENCE Xpedition™ drug eluting stent system
3 January 2013 | By Abbott
FDA approval - XIENCE Xpedition™ Everolimus Eluting Coronary Stent System...
List view / Grid view
News
U.S. FDA Approves ELIQUIS® (apixaban)
2 January 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer announced that the U.S. FDA approved ELIQUIS® (apixaban)...
FDA acknowledgement of resubmission of New Drug Application for Ezetimibe/Atorvastatin tablets
2 January 2013 | By Merck
FDA has acknowledged the resubmission of a New Drug Application...
Abbott completes separation of research-based pharmaceuticals business
2 January 2013 | By Abbott
Abbott has completed the separation of its research-based pharmaceuticals business...
FDA grants accelerated approval for SIRTURO™ (bedaquiline)
31 December 2012 | By Johnson & Johnson
FDA has granted accelerated approval to SIRTURO™ Tablets for the treatment of pulmonary multi-drug resistant tuberculosis...
ELIQUIS® (apixaban) approved in Japan
26 December 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb and Pfizer Inc. announced that the Japanese Ministry of Health, Labor and Welfare has approved ELIQUIS® (apixaban)...
Ryzodeg® (insulin degludec/insulin aspart) approved in Japan
25 December 2012 | By Novo Nordisk
Novo Nordisk announced that the Japanese Ministry of Health, Labour and Welfare has approved Ryzodeg®...
Roche announces FDA approval of Tamiflu for the treatment of influenza in infants
22 December 2012 | By Roche
First medicine approved to treat influenza in infants two weeks of age and older...
Novartis drug Exjade® approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia
21 December 2012 | By Novartis
The EC has approved Exjade®...
Biogen Idec forms first-of-its-kind research consortium to identify ALS drug targets
20 December 2012 | By Biogen Idec
Biogen Idec has created a new research consortium...
Top-line six-month primary treatment period results from first Phase III Fabry monotherapy study
19 December 2012 | By GlaxoSmithKline
Six-month primary treatment period results...
The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development
19 December 2012 | By Novo Nordisk
Novo Nordisk announced the completion of the phase 3a programme for IDegLira...
Merck and GE Healthcare collaborate on use of imaging biomarkers for investigational BACE inhibitor clinical development program
18 December 2012 | By Merck
Clinical study collaboration announced...
GSK and Theravance announce regulatory submission for UMEC/VI (LAMA/LABA) in the US
18 December 2012 | By GlaxoSmithKline
ANORO ELLIPTA™ proposed proprietary name for UMEC/VI...
Sanofi President, Global Operations, to retire
18 December 2012 | By Sanofi
Sanofi announced that Hanspeter Spek, President, Global Operations, will retire from his current role in mid-2013...
